Travere Therapeutics, Inc. (TVTX) announced on Tuesday that it has completed a Type C meeting with the FDA regarding its plan to submit an sNDA for FILSPARI for the treatment of focal segmental glomerulosclerosis.
Focal Segmental Glomerulosclerosis or FSGS, a leading cause of kidney failure, currently has no approved pharmacological treatments.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.